在怀孕早期遵守地中海饮食对恶心,吐和便秘的影响
Isabel Barroso-Ruiz1, Naomi Cano-Ibáñez2,3,4, Rebeca Benito-Villena5,6
1Department of Preventive Medicine and Public Health, Faculty of Medicine, University of Granada, Avda. De la Investigación, 11 18016, Granada, Spain.
Maternal and child health journal
|April 8, 2025
概括
地中海饮食没有显著影响怀孕恶心,吐或便秘. 虽然怀孕期间恶心和吐减少,但便秘不管饮食是否坚持,仍然存在.
科学领域:
- 产科和妇科 产科和妇科
- 营养科学 营养科学
- 胃肠病学 胃肠病学
背景情况:
- 像恶心,吐和便秘这样的孕妇消化系统症状会影响孕妇的生活质量.
- 地中海饮食 (MedDiet) 与健康益处有关,并可能缓解这些症状.
研究的目的:
- 为了确定孕期三个月的孕产妇消化系统症状的患病率.
- 调查遵守地中海饮食和这些症状之间的关联.
主要方法:
- 对237名西班牙孕妇的Walking Preg_Project试验的二次分析.
- 在怀孕12周,19周和32周评估了MedDiet的坚持和消化系统症状 (恶心,吐,便秘).
- 用一个13项调查问卷对MedDiet坚持和怀孕症状目录的症状;多项式分析被采用.
主要成果:
- 恶心和吐的患病率在怀孕32周后显著下降,特别是在那些坚持MedDiet的女性中,与那些坚持MedDiet的女性相比,恶心和吐的患病率显著下降.
- 在任何一组坚持MedDiet的孕妇中,便秘的患病率在整个妊娠期间都没有下降.
- 在基线MedDiet坚持和母亲的胃肠道症状之间没有发现显著的关联.
结论:
- 基线坚持地中海饮食并没有影响怀孕期间恶心,吐或便秘的发生.
- 随着怀孕的进展,恶心和吐自然会减少,而不管是否坚持MedDiet.
- 便秘在整个怀孕期间仍然是一个持续的症状.
更多相关视频
相关概念视频
Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
253
Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
253
Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists
156
5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...
156
Drugs for Treatment of Constipation-Predominant IBS
117
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
117
Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists
197
Dopamine receptor antagonists, also known as antipsychotic agents, are critical in managing chemotherapy-induced vomiting. These antiemetic agents block dopamine receptors in the chemoreceptor trigger zone (CTZ), inhibiting signal transmission to the vomiting center. Antipsychotic agents encompass phenothiazines (PTZ), butyrophenones, benzamides, and thienobenzodiazepines (Zyprexa), which are utilized for their antiemetic and sedative properties.
Phenothiazines, such as prochlorperazine...
Phenothiazines, such as prochlorperazine...
197
Chemotherapy-Induced Nausea and Vomiting: Cannabinoids
192
Tetrahydrocannabinol (THC) is a phytocannabinoid that primarily interacts with the CB1 receptor, a type of G protein-coupled receptor (GPCR) predominantly in and around the chemoreceptor trigger zone (CTZ) and emetic center. THC also blocks the serotonin receptor activity in the dorsal vagal complex (DVC) by inhibiting serotonin release. THC exerts its anti-emetic effects through these interactions, which are beneficial for patients undergoing chemotherapy.
Two synthetic agonists of THC,...
Two synthetic agonists of THC,...
192
Assessment of the Gastrointestinal System I: Subjective Data
127
Assessing the gastrointestinal (GI) system is a complex process that begins with collecting subjective data. This data, collected through patient interviews, provides crucial insights into the patient's health history, perception patterns, and lifestyle habits, all contributing significantly to GI health.
Health History
The initial step in assessing the GI system is obtaining a comprehensive health history. This includes inquiring about the patient's history or presence of problems...
Health History
The initial step in assessing the GI system is obtaining a comprehensive health history. This includes inquiring about the patient's history or presence of problems...
127


